Datar Cancer Genetics gets US FDA breakthrough designation for blood test, TriNetra-Glio to help diagnose brain tumours

Datar Cancer Genetics Inc announced that the US Food and Drug Administration (FDA) has granted 'Breakthrough Device Designation' for its 'TriNetra-Glio', a blood test to help in the diagnosis of brain tumours. This is the third test from the company to have received the Breakthrough Device Designation from the US FDA. The company's early-stage breast and prostate cancer detection tests became the first liquid biopsies to receive the Breakthrough Device Designation. In the United States, brain cancer is the 9th most lethal cancer, and each year, more than 18,000 adults die due to the disease. Diagnosis of brain tumours is risk-prone and brain biopsies are impossible to perform in almost 40% of advanced cases. Presently, no blood test is available for diagnosing brain cancers, and doctors have to rely on complex surgical procedures to obtain tumour tissue for histopathological evaluation. The TriNetra-Glio liquid biopsy is intended to detect the cells released in the blood from the brain tumour; these cells are extremely rare and hard to detect. A prospective, blinded study by a research team at the Imperial College, London, showed the test to be highly accurate. The test requires 15 ml blood and is indicated for patients where a brain biopsy, although necessary, cannot be performed or has been unsuccessful. "In my opinion, a non-invasive blood test that detects circulating tumour cells (CTCs) would help to address many of the problems associated with complex brain tumour diagnosis. As a surgeon working on other technologies to define the tumour and functional boundary during surgery to a molecular level of accuracy and to shorten the diagnostic pathway that would inform surgeons, I find this technology of significant interest. In particular, the intended indication to provide a liquid biopsy diagnosis from a simple blood test where tumours are deemed inoperable or inaccessible will truly address an unmet clinical need. I have found this test to be highly sensitive and specific. This breakthrough technology has true diagnostic utility by detecting cells rather than picking up molecular indicators of disease, which until now liquid biopsies have been based upon," said Dr. Kevin O'Neill, Consultant Neurosurgeon, chairman of the Brain Tumour Research Campaign and Principal Investigator for the Brain Tumour Research Charity's Centre of Excellence working at the Imperial College, London, who led the blinded study to evaluate the test. "The breakthrough designation is a recognition of the potential benefits of TriNetra-Glio in the clinical setting. The test can help individuals where a brain biopsy or surgical resection of the tumour is not possible due to the location of the tumour or other constraints. With our proprietary CTC-enrichment and detection technology, a diagnosis of inaccessible tumours will become possible through a risk-free and patient-friendly blood test," said Dr Vineet Datta, executive director of the company. The test has previously received CE certification and is already available to patients as 'Trublood-CNS'. The Breakthrough Designation is granted by the FDA after rigorous evaluation indicating a reasonable expectation of analytical and clinical success for devices that demonstrate a potential for more effective diagnosis of life-threatening diseases such as cancer. The Breakthrough Devices Program intends to provide patients and healthcare providers with timely access to medical tests and devices granted such designation by prioritized review to expedite development and assessment. With its newly set up facility in Raleigh, North Carolina, Datar will undertake necessary studies for market authorization by the FDA for TriNetra-Glio. The company is also pursuing cutting-edge research for validating multi-analyte approach-based precision treatment options and Circulating Tumour Cell research for early detection of cancer, non-invasive diagnostics, and therapy management.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!